# Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta

Source: https://onco.cc/trials/nct07702032/  
OnCo record `nct07702032` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Petosemtamab, Cetuximab, FOLFIRI in colorectal cancer, run by Genmab, now recruiting.

## Summary

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) is a phase 3 interventional study registered as NCT07702032 by Genmab, with 960 participants planned, started 2026-08-11 and due to reach its primary completion in 2029-07. Interventions recorded: Petosemtamab, Cetuximab, FOLFIRI, mFOLFOX6. Conditions listed: Left-sided Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07702032
- Phase: 3
- Setting: A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
- Sponsor: Genmab
- Enrolled: 960

## Sources

- ClinicalTrials.gov NCT07702032: https://clinicaltrials.gov/study/NCT07702032

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Petosemtamab](https://onco.cc/drugs/petosemtamab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct07702032.json